4 research outputs found
FMR1 premutation and full mutation molecular mechanisms related to autism
Fragile X syndrome (FXS) is caused by an expanded CGG repeat (>200 repeats) in the 5âČ un-translated portion of the fragile X mental retardation 1 gene (FMR1) leading to a deficiency or absence of the FMR1 protein (FMRP). FMRP is an RNA-binding protein that regulates the translation of a number of other genes that are important for synaptic development and plasticity. Furthermore, many of these genes, when mutated, have been linked to autism in the general population, which may explain the high comorbidity that exists between FXS and autism spectrum disorders (ASD). Additionally, premutation repeat expansions (55 to 200 CGG repeats) may also give rise to ASD through a different molecular mechanism that involves a direct toxic effect of FMR1 mRNA. It is believed that RNA toxicity underlies much of the premutation-related involvement, including developmental concerns like autism, as well as neurodegenerative issues with aging such as the fragile X-associated tremor ataxia syndrome (FXTAS). RNA toxicity can also lead to mitochondrial dysfunction, which is common in older premutation carriers both with and without FXTAS. Many of the problems with cellular dysregulation in both premutation and full mutation neurons also parallel the cellular abnormalities that have been documented in idiopathic autism. Research regarding dysregulation of neurotransmitter systems caused by the lack of FMRP in FXS, including metabotropic glutamate receptor 1/5 (mGluR1/5) pathway and GABA pathways, has led to new targeted treatments for FXS. Preliminary evidence suggests that these new targeted treatments will also be beneficial in non-fragile X forms of autism
DatEthics:ethical data-centric design of intelligent behaviour
Abstract
The Internet of Things makes human activity data â what people do, how they move, how they socialise â an abundant resource. However, this rich and intimate perspective on people, which uniquely shape and characterise their behaviours, can have tremendous ethical implication if data is handled irresponsibly. Being personal, contextual and accessible, mobile devices are key facilitators of (ir)responsible collection and use of data. In this workshop, we will use the Future Workshop approach to develop a research agenda towards ethical data-centric design of intelligent behaviours. As part of this approach, we will (1) criticise the current mechanisms and infrastructure to frame ethical challenges, (2) fantasise on futures which support user and designer values, and (3) implement a research agenda for the MobileHCI community to emphasise the barriers to tackle. The outcomes of this workshop will foster ethical research and inspire the MobileHCI community
SIG on Data as Human-Centered Design Material
peer reviewedBehavioral data is ubiquitous in products, services, and systems that people interact with. It is increasingly used by design and HCI researchers and practitioners throughout their human-centered and participatory design processes. The highly dynamic nature of behavioral data makes it deeply intertwined with people, their behavior, and their experiences. Thus, it presents unique opportunities and challenges. This Special Interest Group will provide a space to reflect and discuss effective and responsible ways to engage with behavioral data in human-centered design processes. We will explore questions about the types and scale of data used, the contexts in which data is embedded and applied, the methods we rely on, and the forms of engagement of the multiple stakeholders. In doing so, our goal is to collaboratively develop a research agenda, setting the scope for an annual, international symposium on Data-Centric Design
High Risk of Anal and Rectal Cancer in Patients With Anal and/or Perianal Crohnâs Disease
International audienceBackground & AimsLittle is known about the magnitude of the risk of anal and rectal cancer in patients with anal and/or perineal Crohnâs disease. We aimed to assess the risk of anal and rectal cancer in patients with Crohnâs perianal disease followed up in the Cancers Et Surrisque AssociĂ© aux Maladies Inflammatoires Intestinales En France (CESAME) cohort.MethodsWe collected data from 19,486 patients with inflammatory bowel disease (IBD) enrolled in the observational CESAME study in France, from May 2004 through June 2005; 14.9% of participants had past or current anal and/or perianal Crohnâs disease. Subjects were followed up for a median time of 35 months (interquartile range, 29â40 mo). To identify risk factors for anal cancer in the total CESAME population, we performed a case-control study in which participants were matched for age and sex.ResultsAmong the total IBD population, 8 patients developed anal cancer and 14 patients developed rectal cancer. In the subgroup of 2911 patients with past or current anal and/or perianal Crohnâs lesions at cohort entry, 2 developed anal squamous-cell carcinoma, 3 developed perianal fistulaârelated adenocarcinoma, and 6 developed rectal cancer. The corresponding incidence rates were 0.26 per 1000 patient-years for anal squamous-cell carcinoma, 0.38 per 1000 patient-years for perianal fistulaârelated adenocarcinoma, and 0.77 per 1000 patient-years for rectal cancer. Among the 16,575 patients with ulcerative colitis or Crohnâs disease without anal or perianal lesions, the incidence rate of anal cancer was 0.08 per 1000 patient-years and of rectal cancer was 0.21 per 1000 patient-years. Among factors tested by univariate conditional regression (IBD subtype, disease duration, exposure to immune-suppressive therapy, presence of past or current anal and/or perianal lesions), the presence of past or current anal and/or perianal lesions at cohort entry was the only factor significantly associated with development of anal cancer (odds ratio, 11.2; 95% CI, 1.18-551.51; P = .03).ConclusionsIn an analysis of data from the CESAME cohort in France, patients with anal and/or perianal Crohnâs disease have a high risk of anal cancer, including perianal fistulaârelated cancer, and a high risk of rectal cancer